Structural and Thermodynamic Effects of Macrocyclization in HCV NS3/4A Inhibitor MK-5172

ACS Chemical Biology

Volumn 11, Issue 4, 2016, Pages 900-909

  Soumana, Djadé I ^a   Kurt Yilmaz, Nese ^a   Prachanronarong, Kristina L ^a   Aydin, Cihan ^a,b   Ali, Akbar ^a   Schiffer, Celia A ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b KOÇ UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

GRAZOPREVIR; MACROCYCLIC COMPOUND; NONSTRUCTURAL PROTEIN 3; NONSTRUCTURAL PROTEIN 4A; PROTEINASE; ANTIVIRUS AGENT; MK-5172; NS3 PROTEIN, HEPATITIS C VIRUS; NS4A PROTEIN, FLAVIVIRUS; QUINOXALINE DERIVATIVE; VIRAL PROTEIN;

ANTIVIRAL RESISTANCE; ARTICLE; CONTROLLED STUDY; CRYSTAL STRUCTURE; CYCLIZATION; DRUG BINDING; DRUG POTENCY; ENTHALPY; ENTROPY; ENZYME ACTIVE SITE; HEPATITIS C VIRUS; HYDROGEN BOND; ISOTHERMAL TITRATION CALORIMETRY; MACROCYCLIZATION; MOLECULAR DYNAMICS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; THERMODYNAMICS; VIRUS MUTATION; ANTAGONISTS AND INHIBITORS; CHEMISTRY;

ANTIVIRAL AGENTS; QUINOXALINES; THERMODYNAMICS; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84966283995     PISSN: 15548929     EISSN: 15548937     Source Type: Journal    
DOI: 10.1021/acschembio.5b00647     Document Type: Article

References (57)

1. Alter, M. J. (2007) Epidemiology of hepatitis C virus infection World J. Gastroenterol. 13, 2436-2441 10.3748/wjg.v13.i17.2436
2. Modi, A. A. and Liang, T. J. (2008) Hepatitis C: a clinical review Oral Dis. 14, 10-14 10.1111/j.1601-0825.2007.01419.x
3. World Health Organization. ((2014) Guidelines for the screening, care and treatment of persons with hepatitis C infection, ISBN: 978 92 4 154875, 5th ed.
4. Simmonds, P., Bukh, J., Combet, C., Deleage, G., Enomoto, N., Feinstone, S., Halfon, P., Inchauspe, G., Kuiken, C., Maertens, G., Mizokami, M., Murphy, D. G., Okamoto, H., Pawlotsky, J. M., Penin, F., Sablon, E., Shin, I. T., Stuyver, L. J., Thiel, H. J., Viazov, S., Weiner, A. J., and Widell, A. (2005) Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes Hepatology 42, 962-973 10.1002/hep.20819
5. Gower, E., Estes, C., Blach, S., Razavi-Shearer, K., and Razavi, H. (2014) Global epidemiology and genotype distribution of the hepatitis C virus infection J. Hepatol. 61, S45-57 10.1016/j.jhep.2014.07.027
6. Fried, M. W., Shiffman, M. L., Reddy, K. R., Smith, C., Marinos, G., Goncales, F. L., Jr., Haussinger, D., Diago, M., Carosi, G., Dhumeaux, D., Craxi, A., Lin, A., Hoffman, J., and Yu, J. (2002) Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection N. Engl. J. Med. 347, 975-982 10.1056/NEJMoa020047
7. Bartenschlager, R., Lohmann, V., and Penin, F. (2013) The molecular and structural basis of advanced antiviral therapy for hepatitis C virus infection Nat. Rev. Microbiol. 11, 482-496 10.1038/nrmicro3046
8. Szabo, G. and Bala, S. (2013) MicroRNAs in liver disease Nat. Rev. Gastroenterol. Hepatol. 10, 542-552 10.1038/nrgastro.2013.87
9. Kwong, A. D., Kauffman, R. S., Hurter, P., and Mueller, P. (2011) Discovery and development of telaprevir: an NS3-4A protease inhibitor for treating genotype 1 chronic hepatitis C virus Nat. Biotechnol. 29, 993-1003 10.1038/nbt.2020
10. Perni, R. B., Almquist, S. J., Byrn, R. A., Chandorkar, G., Chaturvedi, P. R., Courtney, L. F., Decker, C. J., Dinehart, K., Gates, C. A., Harbeson, S. L., Heiser, A., Kalkeri, G., Kolaczkowski, E., Lin, K., Luong, Y.-P., Rao, B. G., Taylor, W. P., Thomson, J. A., Tung, R. D., Wei, Y., Kwong, A. D., and Lin, C. (2006) Preclinical profile of VX-950, a potent, selective, and orally bioavailable inhibitor of hepatitis C virus NS3-4A serine protease Antimicrob. Agents Chemother. 50, 899-909 10.1128/AAC.50.3.899-909.2006
11. Malcolm, B. A., Liu, R., Lahser, F., Agrawal, S., Belanger, B., Butkiewicz, N., Chase, R., Gheyas, F., Hart, A., Hesk, D., Ingravallo, P., Jiang, C., Kong, R., Lu, J., Pichardo, J., Prongay, A., Skelton, A., Tong, X., Venkatraman, S., Xia, E., Girijavallabhan, V., and Njoroge, F. G. (2006) SCH 503034, a mechanism-based inhibitor of hepatitis C virus NS3 protease, suppresses polyprotein maturation and enhances the antiviral activity of alpha interferon in replicon cells Antimicrob. Agents Chemother. 50, 1013-1020 10.1128/AAC.50.3.1013-1020.2006
12. Rosenquist, Å., Samuelsson, B., Johansson, P.-O., Cummings, M. D., Lenz, O., Raboisson, P., Simmen, K., Vendeville, S., de Kock, H., Nilsson, M., Horvath, A., Kalmeijer, R., de la Rosa, G., and Beumont-Mauviel, M. (2014) Discovery and Development of Simeprevir (TMC435), a HCV NS3/4A Protease Inhibitor J. Med. Chem. 57, 1673-1693 10.1021/jm401507s
13. Andreone, P., Colombo, M. G., Enejosa, J. V., Koksal, I., Ferenci, P., Maieron, A., Mullhaupt, B., Horsmans, Y., Weiland, O., Reesink, H. W., Rodrigues, L., Jr., Hu, Y. B., Podsadecki, T., and Bernstein, B. (2014) ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection, Gastroenterology 147, 359-365.e351.
14. Yao, N., Reichert, P., Taremi, S. S., Prosise, W. W., and Weber, P. C. (1999) Molecular views of viral polyprotein processing revealed by the crystal structure of the hepatitis C virus bifunctional protease-helicase Structure (Oxford, U. K.) 7, 1353-1363 10.1016/S0969-2126(00)80025-8
15. Love, R. a., Parge, H. E., Wickersham, J. a., Hostomsky, Z., Habuka, N., Moomaw, E. W., Adachi, T., and Hostomska, Z. (1996) The crystal structure of hepatitis C virus NS3 proteinase reveals a trypsin-like fold and a structural zinc binding site Cell 87, 331-342 10.1016/S0092-8674(00)81350-1
16. Appleby, T. C., Anderson, R., Fedorova, O., Pyle, A. M., Wang, R., Liu, X., Brendza, K. M., and Somoza, J. R. (2011) Visualizing ATP-dependent RNA translocation by the NS3 helicase from HCV J. Mol. Biol. 405, 1139-1153 10.1016/j.jmb.2010.11.034
17. Kawai, T., Takahashi, K., Sato, S., Coban, C., Kumar, H., Kato, H., Ishii, K. J., Takeuchi, O., and Akira, S. (2005) IPS-1, an adaptor triggering RIG-I- and Mda5-mediated type I interferon induction Nat. Immunol. 6, 981-988 10.1038/ni1243
18. Li, K., Foy, E., Ferreon, J. C., Nakamura, M., Ferreon, A. C., Ikeda, M., Ray, S. C., Gale, M., Jr., and Lemon, S. M. (2005) Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the Toll-like receptor 3 adaptor protein TRIF Proc. Natl. Acad. Sci. U. S. A. 102, 2992-2997 10.1073/pnas.0408824102
19. Seth, R. B., Sun, L., Ea, C. K., and Chen, Z. J. (2005) Identification and characterization of MAVS, a mitochondrial antiviral signaling protein that activates NF-kappaB and IRF 3 Cell 122, 669-682 10.1016/j.cell.2005.08.012
20. Xu, L. G., Wang, Y. Y., Han, K. J., Li, L. Y., Zhai, Z., and Shu, H. B. (2005) VISA is an adapter protein required for virus-triggered IFN-beta signaling Mol. Cell 19, 727-740 10.1016/j.molcel.2005.08.014
21. Summa, V., Ludmerer, S. W., McCauley, J. A., Fandozzi, C., Burlein, C., Claudio, G., Coleman, P. J., Dimuzio, J. M., Ferrara, M., Di Filippo, M., Gates, A. T., Graham, D. J., Harper, S., Hazuda, D. J., McHale, C., Monteagudo, E., Pucci, V., Rowley, M., Rudd, M. T., Soriano, A., Stahlhut, M. W., Vacca, J. P., Olsen, D. B., Liverton, N. J., and Carroll, S. S. (2012) MK-5172, a selective inhibitor of hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants Antimicrob. Agents Chemother. 56, 4161-4167 10.1128/AAC.00324-12
22. Liverton, N. J., Holloway, M. K., McCauley, J. A., Rudd, M. T., Butcher, J. W., Carroll, S. S., DiMuzio, J., Fandozzi, C., Gilbert, K. F., Mao, S. S., McIntyre, C. J., Nguyen, K. T., Romano, J. J., Stahlhut, M., Wan, B. L., Olsen, D. B., and Vacca, J. P. (2008) Molecular modeling based approach to potent P2-P4 macrocyclic inhibitors of hepatitis C NS3/4A protease J. Am. Chem. Soc. 130, 4607-4609 10.1021/ja711120r
23. Harper, S., McCauley, J. A., Rudd, M. T., Ferrara, M., DiFilippo, M., Crescenzi, B., Koch, U., Petrocchi, A., Holloway, M. K., Butcher, J. W., Romano, J. J., Bush, K. J., Gilbert, K. F., McIntyre, C. J., Nguyen, K. T., Nizi, E., Carroll, S. S., Ludmerer, S. W., Burlein, C., DiMuzio, J. M., Graham, D. J., McHale, C. M., Stahlhut, M. W., Olsen, D. B., Monteagudo, E., Cianetti, S., Giuliano, C., Pucci, V., Trainor, N., Fandozzi, C. M., Rowley, M., Coleman, P. J., Vacca, J. P., Summa, V., and Liverton, N. J. (2012) Discovery of MK-5172, a Macrocyclic Hepatitis C Virus NS3/4a Protease Inhibitor ACS Med. Chem. Lett. 3, 332-336 10.1021/ml300017p
24. Romano, K. P., Ali, A., Aydin, C., Soumana, D., Ozen, A., Deveau, L. M., Silver, C., Cao, H., Newton, A., Petropoulos, C. J., Huang, W., and Schiffer, C. A. (2012) The molecular basis of drug resistance against hepatitis C virus NS3/4A protease inhibitors PLoS Pathog. 8, e1002832 10.1371/journal.ppat.1002832
25. Ali, A., Aydin, C., Gildemeister, R., Romano, K. P., Cao, H., Ozen, A., Soumana, D., Newton, A., Petropoulos, C. J., Huang, W., and Schiffer, C. A. (2013) Evaluating the Role of Macrocycles in the Susceptibility of Hepatitis C Virus NS3/4A Protease Inhibitors to Drug Resistance, ACS Chem. Biol.. 8, 1469 10.1021/cb400100g
26. Romano, K. P., Ali, A., Royer, W. E., and Schiffer, C. A. (2010) Drug resistance against HCV NS3/4A inhibitors is defined by the balance of substrate recognition versus inhibitor binding Proc. Natl. Acad. Sci. U. S. A. 107, 20986-20991 10.1073/pnas.1006370107
27. Driggers, E. M., Hale, S. P., Lee, J., and Terrett, N. K. (2008) The exploration of macrocycles for drug discovery - an underexploited structural class Nat. Rev. Drug Discovery 7, 608-624 10.1038/nrd2590
28. Marsault, E. and Peterson, M. L. (2011) Macrocycles are great cycles: applications, opportunities, and challenges of synthetic macrocycles in drug discovery J. Med. Chem. 54, 1961-2004 10.1021/jm1012374
29. Romano, K. P., Laine, J. M., Deveau, L. M., Cao, H., Massi, F., and Schiffer, C. A. (2011) Molecular mechanisms of viral and host cell substrate recognition by hepatitis C virus NS3/4A protease J. Virol. 85, 6106-6116 10.1128/JVI.00377-11
30. Soumana, D. I., Ali, A., and Schiffer, C. A. (2014) Structural Analysis of Asunaprevir Resistance in HCV NS3/4A Protease, ACS Chem. Biol.. 9, 2485 10.1021/cb5006118
31. Ozen, A., Sherman, W., and Schiffer, C. A. (2013) Improving the Resistance Profile of Hepatitis C NS3/4A Inhibitors: Dynamic Substrate Envelope Guided Design J. Chem. Theory Comput. 9, 5693-5705 10.1021/ct400603p
32. Halfon, P. and Locarnini, S. (2011) Hepatitis C virus resistance to protease inhibitors J. Hepatol. 55, 192-206 10.1016/j.jhep.2011.01.011
33. Pan, D., Xue, W., Zhang, W., Liu, H., and Yao, X. (2012) Understanding the drug resistance mechanism of hepatitis C virus NS3/4A to ITMN-191 due to R155K, A156V, D168A/E mutations: a computational study Biochim. Biophys. Acta, Gen. Subj. 1820, 1526-1534 10.1016/j.bbagen.2012.06.001
34. Doak, B. C., Over, B., Giordanetto, F., and Kihlberg, J. (2014) Oral druggable space beyond the rule of 5: insights from drugs and clinical candidates Chem. Biol. 21, 1115-1142 10.1016/j.chembiol.2014.08.013
35. Giordanetto, F. and Kihlberg, J. (2014) Macrocyclic drugs and clinical candidates: what can medicinal chemists learn from their properties? J. Med. Chem. 57, 278-295 10.1021/jm400887j
36. Clark, V. C., Peter, J. A., and Nelson, D. R. (2013) New therapeutic strategies in HCV: second-generation protease inhibitors Liver Int. 33, 80-84 10.1111/liv.12061
37. Lawitz, E., Sulkowski, M. S., Ghalib, R., Rodriguez-Torres, M., Younossi, Z. M., Corregidor, A., DeJesus, E., Pearlman, B., Rabinovitz, M., Gitlin, N., Lim, J. K., Pockros, P. J., Scott, J. D., Fevery, B., Lambrecht, T., Ouwerkerk-Mahadevan, S., Callewaert, K., Symonds, W. T., Picchio, G., Lindsay, K. L., Beumont, M., and Jacobson, I. M. (2014) Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study Lancet 384, 1756-1765 10.1016/S0140-6736(14)61036-9
38. He, Y., King, M. S., Kempf, D. J., Lu, L., Lim, H. B., Krishnan, P., Kati, W., Middleton, T., and Molla, A. (2008) Relative replication capacity and selective advantage profiles of protease inhibitor-resistant hepatitis C virus (HCV) NS3 protease mutants in the HCV genotype 1b replicon system Antimicrob. Agents Chemother. 52, 1101-1110 10.1128/AAC.01149-07
39. Nijhuis, M., Schuurman, R., de Jong, D., Erickson, J., Gustchina, E., Albert, J., Schipper, P., Gulnik, S., and Boucher, C. A. (1999) Increased fitness of drug resistant HIV-1 protease as a result of acquisition of compensatory mutations during suboptimal therapy AIDS (London, U. K.) 13, 2349-2359 10.1097/00002030-199912030-00006
40. Taremi, S. S., Beyer, B., Maher, M., Yao, N., Prosise, W., Weber, P. C., and Malcolm, B. A. (1998) Construction, expression, and characterization of a novel fully activated recombinant single-chain hepatitis C virus protease Protein Sci. 7, 2143-2149 10.1002/pro.5560071011
41. Otwinowski, Z. and Minor, W. (1997) Processing of X-ray diffraction data collected in oscillation mode, In Methods Enzymol. (Charles, W. Carter, Jr., Ed.), pp 307-326, Academic Press.
42. McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Storoni, L. C., and Read, R. J. (2007) Phaser crystallographic software J. Appl. Crystallogr. 40, 658-674 10.1107/S0021889807021206
43. Adams, P. D., Afonine, P. V., Bunkoczi, G., Chen, V. B., Davis, I. W., Echols, N., Headd, J. J., Hung, L. W., Kapral, G. J., Grosse-Kunstleve, R. W., McCoy, A. J., Moriarty, N. W., Oeffner, R., Read, R. J., Richardson, D. C., Richardson, J. S., Terwilliger, T. C., and Zwart, P. H. (2010) PHENIX: a comprehensive Python-based system for macromolecular structure solution Acta Crystallogr., Sect. D: Biol. Crystallogr. 66, 213-221 10.1107/S0907444909052925
44. Chen, V. B., Arendall, W. B., 3rd, Headd, J. J., Keedy, D. A., Immormino, R. M., Kapral, G. J., Murray, L. W., Richardson, J. S., and Richardson, D. C. (2010) MolProbity: all-atom structure validation for macromolecular crystallography Acta Crystallogr., Sect. D: Biol. Crystallogr. 66, 12-21 10.1107/S0907444909042073
45. Brunger, A. T. (1992) Free R value: a novel statistical quantity for assessing the accuracy of crystal structures Nature 355, 472-475 10.1038/355472a0
46. Emsley, P. and Cowtan, K. (2004) Coot: model-building tools for molecular graphics Acta Crystallogr., Sect. D: Biol. Crystallogr. 60, 2126-2132 10.1107/S0907444904019158
47. Schrodinger, L. (2010) The AxPyMOL Molecular Graphics Plugin for Microsoft PowerPoint, Version 1.0.
48. Nalam, M. N., Ali, A., Altman, M. D., Reddy, G. S., Chellappan, S., Kairys, V., Ozen, A., Cao, H., Gilson, M. K., Tidor, B., Rana, T. M., and Schiffer, C. A. (2010) Evaluating the substrate-envelope hypothesis: structural analysis of novel HIV-1 protease inhibitors designed to be robust against drug resistance J. Virol. 84, 5368-5378 10.1128/JVI.02531-09
49. Schrödinger Release 2014-3: Desmond Molecular Dynamics System, v., D. E. Shaw Research, New York, 2014.
50. Maestro-Desmond Interoperability Tools, version 3.9, Schrödinger, New York, 2014.
51. Bowers, K. J., Xu, H., Dror, R. O., Eastwood, M. P., Gregersen, B. A., Klepeis, J. L., Kolossvary, I., Moraes, M. A., Sacerdoti, F. D., Salmon, J. K., Shan, Y., and Shaw, D. E. (2006) Scalable Algorithms for Molecular Dynamics Simulations on Commodity Clusters, In Proceedings of the 2006 ACM/IEEE conference on Supercomputing, p 746, ACM, Tampa, FL.
52. Jorgensen, W. L., Chandrasekhar, J., Madura, J. D., Impey, R. W., and Klein, M. L. (1983) Comparison of Simple Potential Functions for Simulating Liquid Water J. Chem. Phys. 79, 926-935 10.1063/1.445869
53. Shivakumar, D., Williams, J., Wu, Y., Damm, W., Shelley, J., and Sherman, W. (2010) Prediction of Absolute Solvation Free Energies using Molecular Dynamics Free Energy Perturbation and the OPLS Force Field J. Chem. Theory Comput. 6, 1509-1519 10.1021/ct900587b
54. Ozen, A., Haliloglu, T., and Schiffer, C. A. (2011) Dynamics of preferential substrate recognition in HIV-1 protease: redefining the substrate envelope J. Mol. Biol. 410, 726-744 10.1016/j.jmb.2011.03.053
55. Saalau-Bethell, S. M., Woodhead, A. J., Chessari, G., Carr, M. G., Coyle, J., Graham, B., Hiscock, S. D., Murray, C. W., Pathuri, P., Rich, S. J., Richardson, C. J., Williams, P. A., and Jhoti, H. (2012) Discovery of an allosteric mechanism for the regulation of HCV NS3 protein function Nat. Chem. Biol. 8, 920-925 10.1038/nchembio.1081
56. Abian, O., Vega, S., Sancho, J., and Velazquez-Campoy, A. (2013) Allosteric inhibitors of the NS3 protease from the hepatitis C virus PLoS One 8, e69773 10.1371/journal.pone.0069773
57. Velazquez-Campoy, A., Kiso, Y., and Freire, E. (2001) The Binding Energetics of First- and Second-Generation HIV-1 Protease Inhibitors: Implications for Drug Design Arch. Biochem. Biophys. 390, 169-175 10.1006/abbi.2001.2333